Agios Pharmaceuticals traded at $22.57 this Friday June 24th, increasing $1.29 or 6.06 percent since the previous trading session. Looking back, over the last four weeks, Agios Pharmaceuticals gained 14.98 percent. Over the last 12 months, its price fell by 60.21 percent. Looking ahead, we forecast Agios Pharmaceuticals to be priced at 21.96 by the end of this quarter and at 20.24 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
22.57
Daily Change
6.06%
Yearly
-60.21%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,178.00 28.00 1.30% 8.39%
Daiichi Sankyo 3,312.00 74.00 2.29% 35.46%
AbbVie 152.34 2.89 1.93% 34.84%
Agios Pharmaceuticals 22.57 1.29 6.06% -60.21%
Alnylam Pharmaceuticals 147.50 1.20 0.82% -15.90%
Amgen 245.37 2.28 0.94% 1.11%
Arrowhead Research 34.46 0.20 0.58% -61.85%
AstraZeneca 10,776.00 396.00 3.82% 26.79%
Bayer 57.79 -0.75 -1.28% 11.59%
Biogen 211.93 0.55 0.26% -39.09%
Bluebird Bio 4.40 0.12 2.80% -85.77%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Bristol-Myers Squibb 78.96 1.27 1.63% 18.31%
Epizyme 0.95 -0.003 -0.31% -90.18%
Exelixis 22.22 0.89 4.17% -5.12%
Gilead Sciences 63.08 0.50 0.80% -7.07%
GlaxoSmithKline 1,756.20 36.60 2.13% 24.27%
Immunogen 4.31 -0.06 -1.37% -38.07%
Incyte Corp 78.19 3.41 4.56% -9.95%
Ionis Pharmaceuticals 39.25 0.23 0.59% 0.82%
Jazz Pharmaceuticals 153.49 2.72 1.80% -15.24%
Eli Lilly 325.62 12.90 4.13% 41.44%
Merck & Co 93.13 1.13 1.23% 20.63%
Moderna Inc 144.27 1.01 0.71% -34.40%
Mirati Therapeutics 68.16 2.27 3.45% -58.51%
Nektar Therapeutics 4.03 -0.13 -3.13% -76.66%
Novartis 80.60 2.37 3.03% -4.80%
Novartis 84.83 2.97 3.63% -8.28%
Puma Biotechnology 2.85 -0.05 -1.72% -70.41%
Pfizer 51.59 1.50 2.99% 32.35%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Roche Holding 318.80 12.50 4.08% -7.54%
Seattle Genetics 179.33 5.33 3.06% 14.09%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%
US2000 1766 54.06 3.16% -24.36%

Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.